Methenamine

Methenamine

SCHEMBL204606

C1N2CN3CN1CN(C2)C3.O=C(CNC(=O)c1ccccc1)OC(C(=O)O)c1ccccc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
MDM2 Q00987 1/20 0.45
GPR139 Q6DWJ6 1/20 0.45
KDM4E B2RXH2 1/20 0.45
EPHX2 P34913 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC6A9 P48067 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
OPRK1 P41145 1/20 0.41
KLK7 P49862 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hippuric Acid SCHEMBL1609915 0.76 NPC1 (0.49) GPR139KDM4EEPHX2NPC1RAB9A
Hippuric Acid SCHEMBL2405067 0.76 KDM4E (0.56) GPR139KDM4ENPC1RAB9ASMN1; SMN2
Hippuric Acid SCHEMBL3029 0.76 KDM4E (0.56) GPR139KDM4ENPC1RAB9ASMN1; SMN2
Methenamine SCHEMBL2233803 0.74 LMNA (0.47) ALDH1A1SMN1; SMN2KLK7
SCHEMBL14219258 0.73 GPR139 (0.55) ALDH1A1GPR139KDM4EEPHX2NPC1
SCHEMBL10620106 0.72 CTSK (0.48) ALDH1A1MDM2KDM4EEPHX2SMN1; SMN2
SCHEMBL18219349 0.72 CTSK (0.48) ALDH1A1MDM2KDM4EEPHX2SMN1; SMN2
Hippuric Acid SCHEMBL2464569 0.72 KDM4E (0.56) GPR139KDM4ERAB9ASMN1; SMN2GAA
SCHEMBL5655365 0.70 PRSS1 (0.68) ALDH1A1GPR139NPC1RAB9ASMN1; SMN2
SCHEMBL14219779 0.70 GPR139 (0.51) ALDH1A1GPR139NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351546-B9 LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2024-07-10 EP disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-20240166653-A1 ANTHELMINTIC HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2024-05-23 US disclosed
US-20240132525-A1 BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2024-04-25 US disclosed
US-11964977-B2 Anthelmintic heterocyclic compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-04-23 US disclosed
EP-3351546-B1 LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2024-02-14 EP disclosed
WO-2023244775-A1 BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2023-12-21 WO disclosed
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof Boehringer Ingelheim Animal Health USA Inc. (US) 2023-11-28 US disclosed
EP-4262789-A1 PARASITICIDAL COLLAR COMPRISING ISOXAZOLINE COMPOUNDS Boehringer Ingelheim Vetmedica GmbH (DE) 2023-10-25 EP disclosed
EP-4263559-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2023-10-25 EP disclosed
US-20100125097-A1 COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF MERIAL, INC. 2010-05-20 US disclosed
WO-2010056999-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL LIMITED (US) 2010-05-20 WO disclosed
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2010-05-20 US disclosed
WO-2010048191-A1 THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL LIMITED (US) 2010-04-29 WO disclosed
EP-2155699-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF Merial Limited (US) 2010-02-24 EP disclosed
EP-2035390-A2 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF Aventis Agriculture (FR) 2009-03-18 EP disclosed
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2008-12-18 US disclosed
WO-2008144275-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL LIMITED (US) 2008-11-27 WO disclosed
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof MERIAL, INC. 2008-02-07 US disclosed
WO-2008005489-A2 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF AVENTIS AGRICULTURE (FR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof JAK3, JAK1, JAK2 ALDH1A1 3977/4885MDM2 3176/4885GPR139 4035/4885
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 ALDH1A1 2924/4885MDM2 3937/4885GPR139 1993/4885
US-11964977-B2 Anthelmintic heterocyclic compounds AADAC, HNMT, HRH4 ALDH1A1 651/4885MDM2 4656/4885GPR139 3923/4885
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof CBR3, CBR1, NR5A2 ALDH1A1 3749/4885MDM2 4754/4885GPR139 342/4885
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4X1, CBR3, TYR ALDH1A1 1677/4885MDM2 2252/4885GPR139 2712/4885
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4B1, NPY4R, CYP4X1 ALDH1A1 1144/4885MDM2 1906/4885GPR139 2071/4885
US-20240166653-A1 ANTHELMINTIC HETEROCYCLIC COMPOUNDS AADAC, HNMT, HRH4 ALDH1A1 651/4885MDM2 4656/4885GPR139 3923/4885
US-20100125097-A1 COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF TYR, CAT, NAT1 ALDH1A1 766/4885MDM2 1558/4885GPR139 4834/4885
US-20240132525-A1 BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF JAK2, JAK1, JAK3 ALDH1A1 3629/4885MDM2 2605/4885GPR139 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.